Scharf Camila, Licata Gaetano, Briatico Giulia, Pellerone Sebastiano, Argenziano Giuseppe, Giorgio Caterina Mariarosaria
Dermatology Unit, University of Campania L.Vanvitelli, Naples, Italy.
Dermatology Unit, San Antonio Abate Hospital, Trapani, Italy.
Dermatol Pract Concept. 2023 Apr 1;13(2). doi: 10.5826/dpc.1302a89.
Several dermatological diseases lead to inflammatory conditions of the scalp. Most of these afflictions are recalcitrant and require long term maintenance treatment.
We present a case series where topical tacrolimus was used in a solution vehicle for these conditions.
A total of 22 patients (aged 24-90 years) with confirmed diagnosis of lichen planus pilaris (LPP), discoid lupus (DL), frontal fibrosing alopecia (FFA), erosive pustulosis of the scalp (EPS) or folliculitis decalvans (FD) were evaluated and treated with tacrolimus solution (0.1%) applied twice daily for 1 month, then once daily for another month and alternate days for 4 months. Efficacy was evaluated by an investigator global assessment, clinical and dermoscopic evaluation at weeks 4, 8 and 24. The safety assessment included monitoring of all adverse events.
The study included 13 patients with LPP, 2 with DL, 2 with FD, 2 with EPS and 3 with AFF. After 1 month, 14 patients (63.6%) had a good response and 7 (31.8%) had excellent response. After 2 months, 16 patients (72.7%) had excellent response, and this response was persistent after 6 months of treatment.
Tacrolimus in solution, even if not yet commercially available, was an effective and well tolerated alternative for the maintenance treatment of inflammatory conditions of the scalp.
多种皮肤病会导致头皮出现炎症。这些疾病大多难以治愈,需要长期维持治疗。
我们展示了一个病例系列,其中外用他克莫司以溶液剂型用于这些病症。
共有22例确诊为毛发扁平苔藓(LPP)、盘状红斑狼疮(DL)、额部纤维性秃发(FFA)、头皮糜烂性脓疱病(EPS)或脱发性毛囊炎(FD)的患者(年龄24 - 90岁)接受评估,并使用他克莫司溶液(0.1%)治疗,每天涂抹两次,持续1个月,然后每天涂抹一次,再持续1个月,之后隔天涂抹4个月。在第4、8和24周通过研究者整体评估、临床和皮肤镜评估来评价疗效。安全性评估包括监测所有不良事件。
该研究纳入了13例LPP患者、2例DL患者、2例FD患者、2例EPS患者和3例AFF患者。1个月后,14例患者(63.6%)有良好反应,7例(31.8%)有优异反应。2个月后,16例患者(72.7%)有优异反应,且在治疗6个月后这种反应持续存在。
他克莫司溶液,即使尚未上市,也是头皮炎症性病症维持治疗的一种有效且耐受性良好的替代方法。